TUMOR MICROENVIRONMENT MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2023 - 2030)

Tumor Microenvironment Market, By Cancer Type (Lung Cancer, Colorectal Cancer, Breast Cancer, Prostate Cancer, Bladder Cancer and Others (Melanoma, Kidney cancer, Ovarian cancer etc.)), By Target (T Cells, Tumor-Associated Macrophages, Myeloid-Derived Suppressor Cells, Cancer-Associated Fibroblasts, Regulatory T Cells and Others (Tumor-associated neutrophils, Dendritic cells etc.)), By Therapy (Monoclonal Antibodies, Cytokines, Cancer Vaccines, Oncolytic Viruses, Adoptive Cell Therapies and Others (Gene therapies, Immunomodulators,Checkpoint inhibitors etc.), By End User (Biopharmaceutical Companies, Hospitals, Diagnostic Laboratories, Research Institutes, Contract Research Organizations (CROs) and Others (Academic Institutes and Others), By Geography (North America, Latin America, Europe, Middle East & Africa, and Asia Pacific)

Recent Developments

New product launches

On June 29, 2023, Astellas Pharma Inc., a Japanese multinational pharmaceutical company, and Mitsui Fudosan Co., Ltd., a major real estate developer in Japan, announced that Astellas had established a "TME imaging and interactive research for innovation (TME iLab)" open innovation hub in October 2023 in "MITSUI LINK-Lab KASHIWA-NO-HA 1" (Kashiwa City, Chiba Prefecture, "the Lab"), operated by Mitsui Fudosan.

Acquisition and partnerships

On September 8, 2023, Coherus BioSciences, Inc., a biopharmaceutical company, announced the closing of the previously announced acquisition of Surface Oncology, Inc. (Surface or Surface Oncology), a clinical-stage immuno-oncology (I-O) company developing next-generation immunotherapies that target the tumor microenvironment.
In April 2022, Regeneron Pharmaceuticals, Inc., an American biotechnology company, entered into collaboration with CytomX Therapeutics, Inc., a clinical-stage, oncology-focused biopharmaceutical company, in order to create conditionally-activated investigational bispecific cancer therapies utilizing CytomX's Probody therapeutic platform and Regeneron's Veloci-Bi bispecific antibody development platform.